- PL: The work being done by Sanger is it full genome analysis?
- AK: sí. su approach también es ese para este proyecto.
- JOHN AMUASI: really a rich presentation of the clinical data. Quite a significant variation in the AE.
- AK: We did find larger number of individuals with AE. it was expected. All mild and moderate severity, all self limiting. Non of the participants in the FDC3 had to stop and not take all the doses.